Business
Telo Genomics Receives CLIA Certification
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: ...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Receives CLIA CertificationToronto, Ontario--(Newsfile Corp. - August 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the US Centres of Medicare & Medicaid Services (CMS) which regulates the medical laboratories in the USA, has awarded Telo its Clinical Laboratory Improvement Amendment (\"CLIA\") certificate of registration, as a certified medical clinical laboratory. Telo's registration is within the international stream of CLIA.The CLIA registration and accreditation allows Telo to offer its clinical laboratory services within the USA. The CLIA accreditation also allows the Company to develop and validate its novel TeloView prognostic products and distribute them in the USA and all other international jurisdictions that recognize the International CLIA accreditation. This is a crucial step necessary in making the TeloView diagnostic tests widely available for commercial use and will help advance Telo's platform of prognostic tests across the field of oncology. The CLIA certification, together with the recently achieved CAP accreditation enables Telo to demonstrate to potential US partners the viability of the TeloView prognostic products.Telo worked diligently with the US Centres of Medicare & Medicaid Services for over a year to achieve the CLIA certification, which will entitle the Company to validate its own laboratory tests and add them to its prognostic testing menu.\"The CLIA designation is a game changing milestone for Telo on its path towards commercialization,\" said Jay Wohlgemuth, MD, Managing Partner of Trusted Health Advisors, a strategic advisor to Telo. \"Offering the TeloView portfolio of tests as CLIA tests will empower the ongoing partnership development efforts with key industry players in the diagnostic landscape, particularly in respect to ongoing discussions in smoldering and minimal residual disease (\"MRD\") in multiple myeloma.\"About CLIAThe Clinical Laboratory Improvement Amendments of 1988 (42 USC 263a) and the associated regulations (42 CFR 493) were established by the US Food and Drug Association (FDA) and provides the authority for certifica...